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Teaser: Innovative approaches like the CMap offer new opportunities for drug repositioning and 11 
discovery of new treatments and mechanisms of action, aiding the drug development process in 12 
a cost-effective manner. 13 
14 
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Abstract  15 
There is a paucity of molecules that progress through the drug development pipeline, making 16 
the drug discovery process expensive and frustrating. Innovative approaches to drug 17 
development are therefore required to maximise opportunities. Strategies like the Connectivity 18 
Map (CMap), which compares >7,000 gene expression signatures generated from more than 19 
1,000 drugs, can produce associations between currently unrelated therapeutics, unveiling new 20 
mechanisms of action and favouring drug repositioning. Here, we discuss these opportunities 21 
that could aid the drug development process and propose rigorous publication of ‘omics’ data 22 
with open access and data sharing.  We, pharmacologists of the third millennium, must aim 23 
towards maximising knowledge in an unbiased and cost-effective manner, to deliver new drugs 24 
for the global benefit of patients. 25 
26 
 3 
Main text   27 
As learnt from Darwin’s Origin of Species, it is not the strongest, nor the most intelligent of the 28 
species that survives but the one that is the most adaptable to change. We could extrapolate 29 
this statement to the current situation of the pharmaceutical industry, which seems unable to 30 
sustain its own growth, due to the worldwide challenging economical climate and current 31 
research strategies, perhaps too much seduced by technology and forgetting the unpredictable 32 
nature of research discoveries [1, 2]. There is an unquestionable need for change and a re-33 
invention of the drug development process to guarantee, in a cost-effective manner, the 34 
transition from basic research to patient benefit [3]. 35 
 36 
We now know that patients are not all the same, even if they receive the same diagnosis [4]. 37 
They may belong to a particular disease subtype that might require a specific therapy. The so-38 
called ‘omics’ (a suffix etymologically derived from the Greek, meaning the totality of something) 39 
represent one of the best strategies to reveal differences between patients, as the study of the 40 
totality of the genome, transcriptome, proteome, lipidome or metabolome does not require 41 
previous knowledge on the nature of these differences.  42 
 43 
Genomics, however, can contribute not only to patient stratification [5] but can also impact the 44 
entire drug development process [6], including target identification, deciphering drugs 45 
mechanisms of action, implementation of individualized medicines to seek optimal benefit for 46 
each patient and to monitor drug response and toxicity. In this article we will discuss innovative 47 
whole genome-based strategies that contribute to drug discovery and development by i) 48 
identification of novel treatments for a specific disease, ii) discovery of mechanisms of action of 49 
novel or known compounds and, finally, iii) for drug repositioning studies. We will also highlight 50 
the need for more standardized methods and data-sharing policies to ensure full exploitation of 51 
these findings into genuine clinical benefit. 52 
 53 
Emerging strategies for drug discovery and drug repositioning 54 
The pharmaceutical industry needs to adapt according to the current economical situation. A re-55 
invention of the innovation process is necessary, as technological innovation has not been 56 
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proportionally translated into scientific innovation. Therefore, besides new instruments, new 57 
concepts are needed to improve the efficiency of drug discovery [1, 2]. One of the main 58 
consequences of any genome-wide study is the massive amount of information that is 59 
generated. Whilst analyses of multiple hits can be more sophisticated than simple listing (up- 60 
and down-regulated genes), current approaches tend to follow a more integrated interpretation 61 
from a systems-oriented perspective [7-9]. 62 
 63 
A novel and powerful opportunity derives from the connectivity map (CMap) [10-12]. CMap is 64 
an open-source software that allows a new interpretation of microarray data by comparing gene 65 
expression profiles of interest with those obtained for hundreds of bioactive small molecules, 66 
most of which are FDA-approved drugs. The most recent version (build 02, 67 
http://www.broadinstitute.org/cmap/)) of this database contains 7,056 gene expression profiles 68 
from 1,309 bioactive compounds in 5 different human cell lines. The signatures contained in the 69 
database can be compared with any gene-expression profile of interest following two 70 
approaches: a disease-centered approach, when we use the gene expression profile of a 71 
disease, and a drug-centered approach, when we use the gene expression profile of another 72 
drug of interest. As a result, the 1,309 CMap drugs will be ranked according to the similarity with 73 
the gene-signature of interest. Therefore, drugs with negative score (i.e. they present opposite 74 
profiles to the signature of interest) might have the potential as new treatments for specific 75 
diseases while drugs with positive score (i.e. they have similar gene expression profiles) could 76 
be useful for identification of novel actions of existing drugs or to unravel drug mechanisms of 77 
action [10] (Figure 1). Active efforts are currently being made to increase the capabilities of the 78 
CMap. The new forthcoming version (http://lincscloud.org/) will represent a dramatic expansion 79 
of the database and will contain almost one million of gene expression profiles. In addition to the 80 
expansion in the number of pharmacological perturbagens (over 5,000 compounds), one of the 81 
major novelties of the new CMap will be incorporation of genetic perturbations, that is gene 82 
expression profiles obtained by up-regulation or down-regulation using shRNA of specific 83 
genes, including drug targets and candidate disease genes. 84 
 85 
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Thus, the query of the CMap could be used for drug repositioning, that is, giving novel 86 
indications for an existing drug [13, 14]. For example, the anticonvulsant drug topiramate was 87 
linked (with a negative score) with the gene expression signature of IBD [15]. This prediction 88 
was experimentally assessed using the trinitrobenzenesulfonic (TNBS) acid-induced colitis 89 
model, in which the administration of topiramate significantly reduced intestinal inflammation. 90 
Using a similar approach, the histone deacetylase inhibitor vorinostat was predicted as a 91 
candidate therapeutic drug for gastric cancer, soliciting a series of in vitro investigations to 92 
explore this functional association [16].   It is worth noting, that the CMap was proposed as a 93 
'hypothesis generating tool', which means that confirmation studies are an absolute requirement 94 
to validate initial predictions. Hassane et al. queried the CMap with the gene expression 95 
signature produced by the drug parthenolide on acute myelogenous leukemia (AML) cells. This 96 
drug was previously shown to ablate these cancer cells, and the predictions made with the 97 
CMap led to the identification of novel agents (celastrol and 4-hydroxy-2-nonenal) that could 98 
also markedly affect AML cells [17]. A CMap analysis also allowed Zhong at al to propose a 99 
combination with angiotensin-converting enzyme inhibitors and histone deacetylase inhibitors 100 
as a renoprotective therapy [18] 101 
 102 
Interrogation of the CMap can also serve for the identification of novel mechanisms of action of 103 
drugs. Hypoxia-inducible factor (HIF) 2a inhibitors were found by the CMap to be associated 104 
(positive score) with the anti-inflammatory prostaglandin PGJ2 [19]. This finding incited 105 
subsequent experiments that showed how PGJ2 was acting as an endogenous regulator of 106 
HIF2a translation, suggesting this action as part of the anti-inflammatory effects of the 107 
prostaglandin. The CMap approach has also facilitated identification of novel classes of drugs 108 
including HSP90 inhibitors [20], and dissection of the mechanism of action of a traditional 109 
Chinese medicinal herbal formula [21].  110 
 111 
We have recently queried the CMap using the gene expression signature produced by the 112 
endogenous pro-resolving mediator Annexin A1 (AnxA1) [22]; whilst this analysis produced 113 
predictable associations, e.g. with non-steroidal anti-inflammatory drugs and glucocorticoids, 114 
unexpected associations also emerged. In particular, the positive association with histone 115 
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deacetylase inhibitors (HDACIs) brought us to investigate whether a functional and mechanistic 116 
link between AnxA1 and HDACIs could exist. Further experimentation made us conclude that 117 
AnxA1 contribute to the anti-inflammatory mechanism of action of HDACIs [23].  118 
 119 
Though innovative and promising, the CMap strategy is however not devoid of limitations, 120 
although the new version discussed above might resolve some of them. Firstly, 121 
pharmacologically relevant effects do not necessarily need to be reflected at the transcriptional 122 
level. Secondly, the database was generated with a limited number of compounds and cell 123 
lines. For example, the under-representation of certain drug classes, such as kinase inhibitors in 124 
the current version (build 02) might bias the results. Thirdly, gene expression signatures of 125 
interest are often not measured in the same cells/tissues as those used in the CMap. In 126 
addition, different treatment durations can lead to different results due to feedback regulation of 127 
the target, for example when studying G-protein coupled receptors. Other non-biological 128 
phenomenon such as the "batch effect", which affects the microarrays, compounds and cell 129 
used, can also impact the accuracy of the predictions [24]. Finally, as mentioned before, the 130 
CMap has to be considered a hypothesis-generating tool where results need to be validated by 131 
further experimentation. In any case, its potential could be significant and, indeed, similar 132 
approaches for connecting drugs and genes are starting to emerge. For example, the tool 133 
MANTRA (Mode of Action by NeTwoRk Analysis) allows analysis of the CMap data with an 134 
innovative approach that takes into consideration the variability in the transcriptional responses 135 
to the drug due to cell-line specific effects, different concentrations of drug applied and distinct 136 
experimental conditions [25]. Another example is DvD (Drug versus Disease), a new tool that 137 
combines together the data from the CMap, and the public microarray repositories Gene 138 
Expression Omnibus and Array Express [26]. In addition to new analytical tools, new powerful 139 
technologies such as next generation sequencing (NGS), currently generating data faster than 140 
they can be analyzed, might be incorporated and applied to drug discovery and development 141 
[27]. 142 
 143 
Successful translational research: importance of data-sharing and replication 144 
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Despite the large number of studies using these powerful high-throughput 'omics' analysis 145 
conducted over the last decade, it is striking and concerning the low number of discoveries that 146 
have been translated into practice. To improve these odds, it is absolutely fundamental that 147 
research discoveries are reproduced and validated in independent studies. A recent analysis of 148 
18 microarray studies showed that only 2 were fully reproduced by independent researchers 149 
[28]: the main reason for failure was the unavailability of the data necessary to reproduce the 150 
published results. Similarly, analysis of the top 50 journals with highest impact factors revealed 151 
that only 70% require a mandatory public deposition of microarrays data to guarantee 152 
publication. More surprisingly, even if journals were subjected to data availability policies, 59% 153 
of the articles analysed did not fully adhere to their requirements [29]. Scientific journals should 154 
fully adhere to data-sharing policies to ensure reproducibility as a cornerstone of the scientific 155 
process. Because CMap studies are based on a selection of a number of up- and down-156 
regulated genes obtained from previously conducted microarray analyses, the selection criteria 157 
and the list of genes used for the analysis should be available to ensure transparency and 158 
reproducibility. 159 
 160 
Other publication practices might also be considered, such as the general tendency to publish 161 
the more spectacular results, which might be not fully representative of the true ‘real-life’ result. 162 
Journals should allow and promote publication of independent re-analysis and confirmation 163 
studies, not only initial evidence, as replication is essential for the consolidation of scientific 164 
knowledge and its eventual translation. In addition, underestimation and general refusal of 165 
negative data also distorts the real picture [30, 31]. From the bench side, a more accurate 166 
communication of microarray data is needed, although this aspect has improved thanks to 167 
MIAME (minimum information about a microarray experiment), consisting of a number of 168 
recommendations on the information that needs to be provided to enable the unambiguous 169 
interpretation of microarray-based experimental results [32].  170 
 171 
Challenges and future directions 172 
Despite its slow starting, we truly believe that integration of "omics' into the drug development 173 
process and clinical practice will become a reality in future years. Innovative tools and 174 
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databases promoting the re-use of publicly available information provide new opportunities for 175 
drug development at a low cost [33]. Initiatives like the Connectivity Map described here provide 176 
publicly available tools to extract useful information from whole-genome studies, often not fully 177 
exploited in part due to the difficulty associated to the analysis of large amount of information. 178 
Addition of more gene expression signatures representing more drugs and more cell lines, as it 179 
will happen with forthcoming CMap versions, would increase its usefulness. Data-sharing 180 
policies should be fully implemented and Journals should encourage authors to submit sufficient 181 
details to allow independent assessments of their findings. This transparency is of vital 182 
importance for the performance of meta-analysis, which might help to overcome the variation 183 
between individual studies. 184 
 185 
In conclusion, costs and objective difficulties associated with the drug discovery process require 186 
innovative approaches, where the benefits of available information is maximised.  In this sense, 187 
drug repositioning and identification of new mechanisms represent a low-cost process since 188 
making use of already developed therapeutics: these have often been used in humans, 189 
therefore facilitating rapid testing in clinical settings and rapid completion of drug repositioning. 190 
The CMap can be of great help for this, even more if potentiated with more meaningful protocols 191 
(e.g. use of primary cells).  On the other hand, an organized multi-disciplinary effort is needed, 192 
from basic scientists, clinicians, research journals and regulatory bodies, to make the concept of 193 
translational medicine a reality and not a future perspective. An effort by bio-informatics to make 194 
these powerful tools easy to use and to interpret by basic scientists (biologists, 195 
pharmacologists...) will also be desirable. This must be our priority considering that the ultimate 196 
goal of drug development is improvement of the quality of life of patients. And sooner or later, 197 
we all will be patients! 198 
 199 
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Figure Legends 283 
Figure 1. The Connectivity Map concept. The Connectivity Map (CMap build 02) is a 284 
database that contains the gene expression signatures (obtained with the Affymetrix Genechip 285 
HG-U133A) of more than 1,300 bioactive molecules. Differentially expressed genes were 286 
identified by comparing cells treated with each distinct drug with untreated cells. A gene 287 
expression signature of interest (e.g. of a drug on a particular cell type (A) or a disease (B)) can 288 
be compared with those contained in the CMap database. If the signatures compared are 289 
similar (that will be identified by a 'positive' score), this could potentially be used to predict novel 290 
actions or suggest mechanism of actions of known or novel compounds. On the other hand, 291 
comparisons with a disease signature and identification of a 'negative' score (i.e. the gene 292 
signatures are the opposite) could be used for drug repositioning studies or to suggest new 293 
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treatments for that disease. Experimental validation is further required to confirm hypothesis or 294 
predictions furnished by the CMap. 295 
296 
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